Efficacy and safety of vedolizumab in elderly and younger patients with moderate-to-severe ulcerative colitis: a retrospective real-world study in China
Abstract Background Limited data exist regarding the efficacy and safety of vedolizumab (VDZ) in China’s elderly adult population with ulcerative colitis (UC) in China. In this investigation, a comparative analysis of its efficacy and safety was performed between elderly and younger adult UC cohorts...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-07-01
|
| Series: | BMC Gastroenterology |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12876-025-04125-1 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849332945309925376 |
|---|---|
| author | Hao Zhang Xue-Li Ding Yong-Hong Xu Jun Wu Yue-Yuan Wang Shu-Xian Liu Jing Yan Hua Liu Zi-Bin Tian Ai-Ling Liu |
| author_facet | Hao Zhang Xue-Li Ding Yong-Hong Xu Jun Wu Yue-Yuan Wang Shu-Xian Liu Jing Yan Hua Liu Zi-Bin Tian Ai-Ling Liu |
| author_sort | Hao Zhang |
| collection | DOAJ |
| description | Abstract Background Limited data exist regarding the efficacy and safety of vedolizumab (VDZ) in China’s elderly adult population with ulcerative colitis (UC) in China. In this investigation, a comparative analysis of its efficacy and safety was performed between elderly and younger adult UC cohorts. Methods Patients with moderate-to-severe UC and at least three VDZ infusions at our clinic between March 2021 and November 2024 were retrospectively recruited. The elderly adult patients (≥ 60 years at first VDZ dose) were matched clinically 1:2 to younger patients (18–59 years). Results This study included 30 elderly and 60 younger adult patients. There were no significant differences between the two groups regarding sex, body mass index, percentage of smokers, disease duration, disease extent, disease activity, Mayo endoscopic scores, extra-intestinal manifestations, perianal disease, history of bowel-related surgery, or previous and concomitant therapies. At week 6, the clinical remission and steroid-free clinical remission (SFCR) rates were significantly lower (10.00% vs. 33.33%, P = 0.017; 3.33% vs. 26.67%, P = 0.005) in the elderly group than in the younger group, but there was no significant difference in the clinical response rates (P = 1.000). There was no significant difference in the clinical response, remission, and SFCR rates between the two groups at weeks 14, 22, 38, 46, and 54 (P > 0.05). The frequency of adverse events associated with VDZ was comparable between the two groups (33.33% vs. 38.33%, P = 0.643). Conclusions The efficacy and safety of VDZ in elderly and younger adult patients with UC are similar. Thus, VDZ can be considered both safe and efficacious for treating elderly adult patients with UC. |
| format | Article |
| id | doaj-art-bf1d27a1e3b44674800e2d72e554b6e5 |
| institution | Kabale University |
| issn | 1471-230X |
| language | English |
| publishDate | 2025-07-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Gastroenterology |
| spelling | doaj-art-bf1d27a1e3b44674800e2d72e554b6e52025-08-20T03:46:03ZengBMCBMC Gastroenterology1471-230X2025-07-0125111110.1186/s12876-025-04125-1Efficacy and safety of vedolizumab in elderly and younger patients with moderate-to-severe ulcerative colitis: a retrospective real-world study in ChinaHao Zhang0Xue-Li Ding1Yong-Hong Xu2Jun Wu3Yue-Yuan Wang4Shu-Xian Liu5Jing Yan6Hua Liu7Zi-Bin Tian8Ai-Ling Liu9Department of Gastroenterology, The Affiliated Hospital of Qingdao UniversityDepartment of Gastroenterology, The Affiliated Hospital of Qingdao UniversityDepartment of Gastroenterology, The Affiliated Hospital of Qingdao UniversityDepartment of Gastroenterology, The Affiliated Hospital of Qingdao UniversityDepartment of Gastroenterology, The Affiliated Hospital of Qingdao UniversityDepartment of Gastroenterology, The Affiliated Hospital of Qingdao UniversityDepartment of Gastroenterology, The Affiliated Hospital of Qingdao UniversityDepartment of Gastroenterology, The Affiliated Hospital of Qingdao UniversityDepartment of Gastroenterology, The Affiliated Hospital of Qingdao UniversityDepartment of Gastroenterology, The Affiliated Hospital of Qingdao UniversityAbstract Background Limited data exist regarding the efficacy and safety of vedolizumab (VDZ) in China’s elderly adult population with ulcerative colitis (UC) in China. In this investigation, a comparative analysis of its efficacy and safety was performed between elderly and younger adult UC cohorts. Methods Patients with moderate-to-severe UC and at least three VDZ infusions at our clinic between March 2021 and November 2024 were retrospectively recruited. The elderly adult patients (≥ 60 years at first VDZ dose) were matched clinically 1:2 to younger patients (18–59 years). Results This study included 30 elderly and 60 younger adult patients. There were no significant differences between the two groups regarding sex, body mass index, percentage of smokers, disease duration, disease extent, disease activity, Mayo endoscopic scores, extra-intestinal manifestations, perianal disease, history of bowel-related surgery, or previous and concomitant therapies. At week 6, the clinical remission and steroid-free clinical remission (SFCR) rates were significantly lower (10.00% vs. 33.33%, P = 0.017; 3.33% vs. 26.67%, P = 0.005) in the elderly group than in the younger group, but there was no significant difference in the clinical response rates (P = 1.000). There was no significant difference in the clinical response, remission, and SFCR rates between the two groups at weeks 14, 22, 38, 46, and 54 (P > 0.05). The frequency of adverse events associated with VDZ was comparable between the two groups (33.33% vs. 38.33%, P = 0.643). Conclusions The efficacy and safety of VDZ in elderly and younger adult patients with UC are similar. Thus, VDZ can be considered both safe and efficacious for treating elderly adult patients with UC.https://doi.org/10.1186/s12876-025-04125-1Ulcerative colitisVedolizumabElderlyEfficacySafety |
| spellingShingle | Hao Zhang Xue-Li Ding Yong-Hong Xu Jun Wu Yue-Yuan Wang Shu-Xian Liu Jing Yan Hua Liu Zi-Bin Tian Ai-Ling Liu Efficacy and safety of vedolizumab in elderly and younger patients with moderate-to-severe ulcerative colitis: a retrospective real-world study in China BMC Gastroenterology Ulcerative colitis Vedolizumab Elderly Efficacy Safety |
| title | Efficacy and safety of vedolizumab in elderly and younger patients with moderate-to-severe ulcerative colitis: a retrospective real-world study in China |
| title_full | Efficacy and safety of vedolizumab in elderly and younger patients with moderate-to-severe ulcerative colitis: a retrospective real-world study in China |
| title_fullStr | Efficacy and safety of vedolizumab in elderly and younger patients with moderate-to-severe ulcerative colitis: a retrospective real-world study in China |
| title_full_unstemmed | Efficacy and safety of vedolizumab in elderly and younger patients with moderate-to-severe ulcerative colitis: a retrospective real-world study in China |
| title_short | Efficacy and safety of vedolizumab in elderly and younger patients with moderate-to-severe ulcerative colitis: a retrospective real-world study in China |
| title_sort | efficacy and safety of vedolizumab in elderly and younger patients with moderate to severe ulcerative colitis a retrospective real world study in china |
| topic | Ulcerative colitis Vedolizumab Elderly Efficacy Safety |
| url | https://doi.org/10.1186/s12876-025-04125-1 |
| work_keys_str_mv | AT haozhang efficacyandsafetyofvedolizumabinelderlyandyoungerpatientswithmoderatetosevereulcerativecolitisaretrospectiverealworldstudyinchina AT xueliding efficacyandsafetyofvedolizumabinelderlyandyoungerpatientswithmoderatetosevereulcerativecolitisaretrospectiverealworldstudyinchina AT yonghongxu efficacyandsafetyofvedolizumabinelderlyandyoungerpatientswithmoderatetosevereulcerativecolitisaretrospectiverealworldstudyinchina AT junwu efficacyandsafetyofvedolizumabinelderlyandyoungerpatientswithmoderatetosevereulcerativecolitisaretrospectiverealworldstudyinchina AT yueyuanwang efficacyandsafetyofvedolizumabinelderlyandyoungerpatientswithmoderatetosevereulcerativecolitisaretrospectiverealworldstudyinchina AT shuxianliu efficacyandsafetyofvedolizumabinelderlyandyoungerpatientswithmoderatetosevereulcerativecolitisaretrospectiverealworldstudyinchina AT jingyan efficacyandsafetyofvedolizumabinelderlyandyoungerpatientswithmoderatetosevereulcerativecolitisaretrospectiverealworldstudyinchina AT hualiu efficacyandsafetyofvedolizumabinelderlyandyoungerpatientswithmoderatetosevereulcerativecolitisaretrospectiverealworldstudyinchina AT zibintian efficacyandsafetyofvedolizumabinelderlyandyoungerpatientswithmoderatetosevereulcerativecolitisaretrospectiverealworldstudyinchina AT ailingliu efficacyandsafetyofvedolizumabinelderlyandyoungerpatientswithmoderatetosevereulcerativecolitisaretrospectiverealworldstudyinchina |